CA2561146C - 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1h-pyrrolo[2-,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine for use in treating hiv infection - Google Patents

1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1h-pyrrolo[2-,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine for use in treating hiv infection Download PDF

Info

Publication number
CA2561146C
CA2561146C CA2561146A CA2561146A CA2561146C CA 2561146 C CA2561146 C CA 2561146C CA 2561146 A CA2561146 A CA 2561146A CA 2561146 A CA2561146 A CA 2561146A CA 2561146 C CA2561146 C CA 2561146C
Authority
CA
Canada
Prior art keywords
hiv
aids
compound
agent
hiv infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2561146A
Other languages
English (en)
French (fr)
Other versions
CA2561146A1 (en
Inventor
Pin-Fang Lin
Beata Nowicka-Sans
Gregory Yamanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ViiV Healthcare UK No 4 Ltd
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34961940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2561146(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CA2561146A1 publication Critical patent/CA2561146A1/en
Application granted granted Critical
Publication of CA2561146C publication Critical patent/CA2561146C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2561146A 2004-03-24 2005-03-01 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1h-pyrrolo[2-,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine for use in treating hiv infection Expired - Lifetime CA2561146C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55576704P 2004-03-24 2004-03-24
US60/555,767 2004-03-24
PCT/US2005/006277 WO2005102392A2 (en) 2004-03-24 2005-03-01 Combinations for treating hiv infection

Publications (2)

Publication Number Publication Date
CA2561146A1 CA2561146A1 (en) 2005-11-03
CA2561146C true CA2561146C (en) 2013-12-24

Family

ID=34961940

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2561146A Expired - Lifetime CA2561146C (en) 2004-03-24 2005-03-01 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1h-pyrrolo[2-,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine for use in treating hiv infection

Country Status (30)

Country Link
US (1) US7776863B2 (enExample)
EP (1) EP1732604B1 (enExample)
JP (1) JP4847441B2 (enExample)
KR (1) KR101158140B1 (enExample)
CN (1) CN1956720B (enExample)
AR (1) AR048333A1 (enExample)
AT (1) ATE474602T1 (enExample)
AU (1) AU2005235116B2 (enExample)
BR (1) BRPI0509140A (enExample)
CA (1) CA2561146C (enExample)
CY (1) CY1111613T1 (enExample)
DE (1) DE602005022420D1 (enExample)
DK (1) DK1732604T3 (enExample)
ES (1) ES2347801T3 (enExample)
GE (1) GEP20104925B (enExample)
HR (1) HRP20100434T1 (enExample)
IL (1) IL178141A (enExample)
IN (1) IN2012DN06436A (enExample)
MY (1) MY144318A (enExample)
NO (1) NO337116B1 (enExample)
NZ (1) NZ549778A (enExample)
PE (1) PE20060148A1 (enExample)
PL (1) PL1732604T3 (enExample)
PT (1) PT1732604E (enExample)
RU (1) RU2367439C2 (enExample)
SI (1) SI1732604T1 (enExample)
TW (1) TWI347184B (enExample)
UA (1) UA88463C2 (enExample)
WO (1) WO2005102392A2 (enExample)
ZA (1) ZA200607959B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
EP2657235A1 (en) 2005-10-28 2013-10-30 Ono Pharmaceutical Co., Ltd. Compound containing basic group and use thereof
WO2007058322A1 (ja) 2005-11-18 2007-05-24 Ono Pharmaceutical Co., Ltd. 塩基性基を含有する化合物およびその用途
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US7501419B2 (en) * 2006-04-25 2009-03-10 Bristol-Myers Squibb Company 4-Squarylpiperazine derivatives as antiviral agents
US7504399B2 (en) 2006-06-08 2009-03-17 Bristol-Meyers Squibb Company Piperazine enamines as antiviral agents
US7572810B2 (en) * 2006-06-08 2009-08-11 Bristol-Myers Squibb Company Alkene piperidine derivatives as antiviral agents
JP5433691B2 (ja) * 2008-06-25 2014-03-05 ブリストル−マイヤーズ スクイブ カンパニー Ｈｉｖ結合阻害剤としてのジケトピペリジン誘導体
WO2009158394A1 (en) * 2008-06-25 2009-12-30 Bristol-Myers Squibb Company Diketo azolopiperidines and azolopiperazines as anti-hiv agents
US20110293686A1 (en) * 2010-05-28 2011-12-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-viral compositions and methods for administration
WO2012019003A1 (en) 2010-08-06 2012-02-09 Bristol-Myers Squibb Company Substituted indole and azaindole oxoacetyl piperazinamide derivatives
ES2585396T3 (es) 2010-12-02 2016-10-05 VIIV Healthcare UK (No.5) Limited Alquilamidas como inhibidores de la unión del VIH
DK2670751T3 (en) 2011-01-31 2015-07-20 Bristol Myers Squibb Co PROCEDURES FOR MANUFACTURING HIV BINDING INHIBITOR PRODUCT CONNECTION AND INTERMEDIATES
WO2012142080A1 (en) 2011-04-12 2012-10-18 Bristol-Myers Squibb Company Thioamide, amidoxime and amidrazone derivatives as hiv attachment inhibitors
US8664213B2 (en) 2011-08-29 2014-03-04 Bristol-Myers Squibb Company Spiro bicyclic diamine derivatives as HIV attachment inhibitors
WO2013033061A1 (en) 2011-08-29 2013-03-07 Bristol-Myers Squibb Company Fused bicyclic diamine derivatives as hiv attachment inhibitors
WO2013138436A1 (en) 2012-03-14 2013-09-19 Bristol-Myers Squibb Company Cyclolic hydrazine derivatives as hiv attachment inhibitors
EP2895472B1 (en) 2012-08-09 2016-11-23 VIIV Healthcare UK (No.5) Limited Tricyclic alkene derivatives as HIV attachment inhibitors
WO2014025854A1 (en) 2012-08-09 2014-02-13 Bristol-Myers Squibb Company Piperidine amide derivatives as hiv attachment inhibitors
US9586957B2 (en) * 2013-03-27 2017-03-07 VIIV Healthcare UK (No.5) Limited 2-keto amide derivatives as HIV attachment inhibitors
CN107847514A (zh) * 2015-06-23 2018-03-27 西托戴恩股份有限公司 炎症、癌症、自身免疫和其它病症中ccl5配体结合ccr5受体的抑制作用和ccr5/ccl5轴信号传导的改变
WO2023172635A1 (en) * 2022-03-08 2023-09-14 Emory University Predictive model for variants associated with drug resistance and theranostic applications thereof
US12425371B2 (en) * 2022-09-16 2025-09-23 Cisco Technology, Inc. System and method for providing SCHC-based edge firewalling

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU762404B2 (en) * 1998-03-02 2003-06-26 Panacos Pharmaceuticals, Inc. Acylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
US6476034B2 (en) 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20030207910A1 (en) 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
RU2192870C1 (ru) * 2001-07-02 2002-11-20 Закрытое акционерное общество "Агрофарм ПитерСиб" Антивирусная композиция, способ получения ее активной компоненты и способ лечения вич-инфицированных больных этой композицией
CA2469592C (en) * 2001-12-12 2005-08-23 Bristol-Myers Squibb Company Hiv integrase inhibitors
PL369856A1 (en) * 2001-12-21 2005-05-02 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy

Also Published As

Publication number Publication date
EP1732604B1 (en) 2010-07-21
HK1096540A1 (en) 2007-06-01
RU2367439C2 (ru) 2009-09-20
AU2005235116B2 (en) 2011-03-31
JP2007530540A (ja) 2007-11-01
IL178141A0 (en) 2006-12-31
IN2012DN06436A (enExample) 2015-10-09
IL178141A (en) 2010-11-30
ATE474602T1 (de) 2010-08-15
US7776863B2 (en) 2010-08-17
CA2561146A1 (en) 2005-11-03
RU2006137555A (ru) 2008-04-27
TWI347184B (en) 2011-08-21
NO20064547L (no) 2006-10-06
DK1732604T3 (da) 2010-11-15
KR20070011322A (ko) 2007-01-24
GEP20104925B (en) 2010-03-25
WO2005102392A2 (en) 2005-11-03
NZ549778A (en) 2010-09-30
MY144318A (en) 2011-08-29
ZA200607959B (en) 2008-06-25
CN1956720A (zh) 2007-05-02
HRP20100434T1 (hr) 2010-09-30
SI1732604T1 (sl) 2010-10-29
PE20060148A1 (es) 2006-03-04
PT1732604E (pt) 2010-09-24
CN1956720B (zh) 2010-12-15
AU2005235116A1 (en) 2005-11-03
AR048333A1 (es) 2006-04-19
NO337116B1 (no) 2016-01-25
EP1732604A2 (en) 2006-12-20
KR101158140B1 (ko) 2012-06-19
US20050215545A1 (en) 2005-09-29
UA88463C2 (ru) 2009-10-26
TW200538117A (en) 2005-12-01
JP4847441B2 (ja) 2011-12-28
WO2005102392A3 (en) 2006-07-20
PL1732604T3 (pl) 2010-12-31
BRPI0509140A (pt) 2007-09-04
DE602005022420D1 (de) 2010-09-02
CY1111613T1 (el) 2015-10-07
ES2347801T3 (es) 2010-11-04

Similar Documents

Publication Publication Date Title
CA2561146C (en) 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1h-pyrrolo[2-,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine for use in treating hiv infection
US20050215544A1 (en) Methods of treating HIV infection
US20050215543A1 (en) Methods of treating HIV infection
US20060058286A1 (en) Methods of treating HIV infection
De Clercq Emerging anti-HIV drugs
Flexner Antiretroviral agents and treatment of HIV infection
AU2006325404B2 (en) Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit
RS57323B1 (sr) Antivirusna terapija
US20190125875A1 (en) ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED Ph EFFECT
US7449476B2 (en) Tetrahydrocarboline antiviral agents
MX2012011415A (es) Terapia de combinacion que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinetico.
HK1096540B (en) Methods of treating hiv infection
MXPA06010885A (es) Combinaciones para tratamiento de infeccion de virus de inmunodeficiencia humana (vih)
De Clercq et al. Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile: retroviruses and hepadnaviruses
Uckun et al. Therapeutic innovations against HIV
Reviriego Cenicriviroc mesylate
US20030181436A1 (en) Treatment for AIDS, HIV, and other related diseases and compounds for use therewith
Revill et al. Apricitabine

Legal Events

Date Code Title Description
EEER Examination request